The therapy is derived from the blood plasma of healthy donors recovered from COVID-19 and has the potential to be a highly specific and pure drug that delivers a high and consistent concentration of protective antibodies against SARS-CoV-2. The company has been collecting COVID-19 convalescent plasma since April in more than 245 Grifols U.S. donation centers.

The company's research efforts are in part supported by the U.S. Food and Drug Administration, the National Institutes of Health, and the Biomedical Advanced Research Development Authority.

In addition to U.S. clinical trials, the company is working on a European clinical trial of the hyperimmune globulin therapy using COVID-19 convalescent plasma collected in Europe.

Grifols begins production of COVID-19 immunotherapy
Grifols will start production of anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using plasma from patients who have recovered from...